Novartis Institutes for BioMedical Research Inc.
www.nibr.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Novartis Institutes for BioMedical Research Inc.
Amgen Doubles Down On AI, Genomic Investments In R&D
David Reese, chief technology officer and former EVP of R&D, and newly appointed EVP of R&D Jay Bradner spoke with Scrip about how Amgen is pairing artificial intelligence with genomics plus data milestones in 2024.
Amgen Expands R&D C-Suite As Reese Focuses On Technology, Bradner Leads R&D
Amgen appointed R&D head David Reese as EVP and chief technology officer and recruited former Novartis executive Jay Bradner as EVP of R&D and chief scientific officer.
Who Wants To Live Forever? Forging A Regulatory Pathway For Longevity Drugs
Despite the growing interest, both in and outside of the biotech space, in the so-called ‘longevity’ industry, no regulatory pathway exists to market a drug with a purely geroprotective indication.
J&J-Bound Reed Reaches End Of The Road As Sanofi R&D Chief
The French drugmaker has begun an external and internal search to succeed John Reed who is heading for Johnson & Johnson after an up-and-down five years as Sanofi’s R&D chief.
Company Information
- Industry
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice